Q3 2024 PAVmed Inc Earnings Call Transcript
Key Points
- PAVmed Inc (PAVM) reported a transformational quarter with strategic steps to strengthen its corporate structure and balance sheet.
- The company successfully deconsolidated Lucid Diagnostics, preserving ownership without absorbing operating losses.
- PAVmed Inc (PAVM) restructured its convertible debt, allowing it to maintain its Nasdaq listing.
- Lucid Diagnostics reported record revenue with a 20% increase quarter-on-quarter.
- Veris Health received a $1.8 million NIH grant to optimize its Cancer Care Platform for underserved patients.
- The deconsolidation of Lucid Diagnostics led to a significant change in PAVmed Inc (PAVM)'s financial presentation, complicating comparisons.
- The restructuring process delayed the capital raise for Veris Health, potentially affecting timelines for product development.
- PAVmed Inc (PAVM) is reliant on obtaining direct funding for further R&D expenses, which could impact future operations if not secured.
- The company faces challenges in maintaining sustainable compliance with Nasdaq listing standards.
- The delay in financing may push the FDA submission for Veris Health's implantable monitor into the second half of 2025.
Good morning, and welcome to the PAVmed's third-quarter 2024 business update conference call. (Operator Instructions) Please note this event is being recorded.
I would now like to turn the conference over to Matt Riley, PAVmed Director of Investor Relations. Please go ahead.
Thank you, operator, and good morning, everyone. Thank you for participating in today's business update call. Joining me today on the call are Dr. Lishan Aklog, Chairman and Chief Executive Officer of PAVmed; along with Dennis McGrath, Chief Financial Officer of PAVmed.
The press release announcing our business update and financial results is available on PAVmed's website. Please take a moment to read the disclaimers about forward-looking statements in the press release. The business update press release and the conference call all include forward-looking statements, and these forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from the statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
